Last reviewed · How we verify
NCT07243132: LUNGEVITY
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
trial testing Hospital Anxiety and Depression scale (HAD) in Metastatic Lung Cancer in 1,000 participants. Currently enrolling.
31 January 2031
Quick facts
| Lead sponsor | GFPC Investigation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 2 July 2025 |
| Primary completion | 31 January 2031 |
| Estimated completion | 31 January 2031 |
| Sites | 46 locations across France |
Drugs / interventions tested
- Hospital Anxiety and Depression scale (HAD)
- Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)
- Questionnaire Aix-Marseille-Université (AMU)
Conditions studied
- Metastatic Lung Cancer — all drugs for Metastatic Lung Cancer →
- Metastatic NSCLC — all drugs for Metastatic NSCLC →
- Metastatic Small Cell Lung Cancer — all drugs for Metastatic Small Cell Lung Cancer →
Sponsor
GFPC Investigation
Who can join
18 and older, any sex, with Metastatic Lung Cancer or Metastatic NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07243132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Lung Cancer
Currently open trials in the same condition.
- NCT06781905 — Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung · recruiting
- NCT06481813 — Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients · NA · recruiting
- NCT06165419 — Definitive Radiation for High-Risk Spine Metastases · Phase 2 · recruiting
- NCT06060613 — Safety and Efficacy of OBX-115 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT05502913 — Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer · Phase 2 · recruiting
Other GFPC Investigation trials
Trials by the same sponsor.
- NCT06646471 — PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07243132 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GFPC Investigation
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07243132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing